Figure 3: Serum levels of uPA are increased in IPF.
From: The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF
Sera (10 μg protein) from IPF or control donors in parallel were resolved by SDS-PAGE and immunoblotted for uPA. (a) Blots of serum samples showing overall protein loading by Ponceau red staining and both the high and low molecular weight forms of uPA (~54 and 31 kDa, respectively). Lane 1 is serum from a control donor, whereas lanes 2 and 3 are sera from separate IPF donors. (b) The relative levels of total uPA (high and low MW forms combined) in serum based on densitometry analysis. **P < 0.01 (n = 18 IPF and n = 18 non-IPF). (c) The percentage of low MW uPA to total uPA. *P < 0.05. (d–f) The relationships between uPA levels of IPF patients and lung function as measured by the % predicted values of FVC, FEV1 and DLCO. The solid line is the regression line, whereas the dotted lines represent the 95% confidence intervals. Data (d–f) were analyzed using the Pearson’s correlation test, with r and P (one-tailed) values provided.
